

**PB 115 of 2025**

National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 9) 2025

I, Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.

Dated 29 September 2025

**REBECCA RICHARDSON**

Assistant Secretary

PBS Listing, Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health, Disability and Ageing

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) 2

1 Name

(1) This instrument is the *National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 9) 2025.*

(2)This instrument may also be cited as PB 115 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 October 2025 |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 85AB(1) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1. **Schedule 1, after item dealing with Cannabidiol**

Insert:

Capivasertib

1. **Schedule 1, after item dealing with Lorlatinib**

Insert:

Lumasiran

1. **Schedule 2, after item dealing with Adalimumab**

Omit:

Adefovir

1. **Schedule 2, after item dealing with Ivabradine**

Omit:

Ketoprofen